2022 American Transplant Congress

TOPIC: Clinical Science » Kidney » 38 - Kidney Immunosuppression: Novel Regimens and Drug Minimization

Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)
G. Divard¹, O. Aubert¹, M. Raynaud¹, F. Vincenti², L. Rostaing³, A. Durbach⁴, C. Legendre¹, R. Vadanici⁵, A. Loupy¹, -. BENEFIT & BENEFIT-EXT Investigators⁶
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²
XR Tacrolimus Dosing By Ideal Body Weight Reduces Incidence Of Early Supratherapeutic Tacrolimus Concentrations
G. Codispodo, J. Hedvat, D. Salerno, N. Lange